As for other targeted drugs, EGFR-TKI treatment provokes over time the emergence of resistant clones, which can be present before the therapy begins or originate de novo from pools of tolerant/persister cells8–11, eventually resulting in tumor relapse. This evidence concerns the gene EGFR and neoplasm.